Of the 33,745 individuals with a diagnosis of dementia in the sample, 8,897 (25.4%) had Alzheimer disease, and 21,972 (74.7%) had other types of dementia. The annual incidence of Alzheimer disease in the United States is 5.9 per 100,000 inhabitants per year.
There is no cure for Alzheimer's disease, because no therapy is effective for the disease itself but is available to delay the progressive damage of the disease. At present, research interventions include treatments for people who have Alzheimer's Disease, and research into new medicines are ongoing. Patients can help by encouraging their family members to become involved in Alzheimer's disease research; if they know that there is no cure for the disease, they are more likely to be supportive, as well as providing care for family members who have or are at risk of developing the condition.
Results from a recent clinical trial presents the majority of existing therapies for Alzheimers disease. This article mainly emphasizes the use of currently available medications and treatments for the disease. This article did not include many innovative techniques that show a promising result for further development by the scientific community, such as anti-amyloid approaches.
This section summarizes how Alzheimer's Disease (AD) is characterized. AD is a disease that begins slowly and worsens with no specific risk factors. The typical symptoms include behavioral changes such as decreased social skills, problems with memory and thinking, and other signs of mind change like inability to talk or walk or changes in hearing and vision. By the time symptoms are recognized AD usually has progressed to a late stage, when the brain's ability to support the mind is exhausted.\n
It is not completely clear why so many elderly people develop AD. However, it is known that genetic, environmental, and lifestyle factors play a role the development of AD. Aspects of diet that are associated with the risk and severity of AD are obesity, the consumption of alcoholic beverages and the use of non-steroidal anti-inflammatory drugs. Other environmental factors found to be associated with the development of AD include pollutants such as dioxin that are derived from industrial emissions.\n
For many people, the first symptom of probable AD is difficulty with recalling names or personal information; this may be the only sign they see that suggests that they may have early AD. Most adults will develop a significant degree of cognitive decline, but by the time they receive a diagnosis the problem has mostly resolved; the term prodromal AD applies to milder levels of cognitive impairment such as episodic memory and executive function difficulties earlier in the disease progression. There may still be difficulty with some cognitive functions such as visual memory, though, and some patients with AD may have no cognitive or physical signs at all. There may be other signs such as changes in personality.
Current research findings are hopeful for the treatment of Alzheimer's disease. One type of treatments involves [neuroprotection agents]. Neuroprotective agents are [protein precursors that] try to protect biological neurons from damage by the accumulation of [amyloid] plaques and tangles. These pre-clinical discoveries suggest that future treatments may show some success in treating Alzheimer's disease. There are currently no medications approved for the treatment of Alzheimer's disease. However, many [neuroprotectants] are in clinical trials [in 2016, 2017], so future research and treatment may show some success. [Power](http://www.withpower.
The prevalence of AD in Italy is higher than anywhere else in the world. The disease has major impact on patients' well-being: they usually have dementia. Alzheimer disease is the most frequent cause of dementia; it is responsible for a quarter of all dementia cases (5-20% of all cases in the general population). Moreover, almost all patients also have Alzheimer-related problems like aggression, agitation and behavioural problems. There are also a small number of patients affected by other forms of dementia like vascular dementia, frontotemporal dementia and Lewy body dementia. Therefore, the prevalence of AD is underestimated in Italy.
Findings from a recent study shows that star-vtf can be a feasible and practical approach to virtual training of seniors. Because of such, star-vtf should be developed further.
Starvtf can reduce dementia symptomatology after only one session. Starvtf can be used at home as a form of patient education and support, with the help of a qualified caregiver. This is an inexpensive and simple method for helping caregivers get the care they require.
Star-vtf provides personalized VFT that can improve cognition, behavior and emotion and may reduce depressive symptoms. A further reduction in cost and time saved compared with traditional VFT will encourage improved use of this inexpensive, free, therapeutic VFT modality.
While the most common form of this disease is undoubtedly Alzheimer disease, the disease may also be associated with some other, less-common types of dementia and other diseases, or is accompanied by symptoms of psychosis, hallucinations, delusions, and abnormal behavior. The most recent revision of the nosology is not a revision of the primary pathology; it may be a revision of the symptoms and symptoms that can be seen in some of the disorders that can be called Alzheimer's disease. Clinically defined Alzheimer's disease and other forms of senile dementia may be grouped together and have some common pathologic factors, but it is certainly a misnomer to suggest that this is a revision of a primary pathology.